The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City
Alberto Cedro-Tanda | Laura Gómez-Romero | Nicolás Alcaraz | Guillermo de Anda-Jauregui | Fernando Peñaloza | Bernardo Moreno | Marco A. Escobar-Arrazola | Oscar A. Ramirez-Vega | Paulina Munguia-Garza | Francisco Garcia-Cardenas | Mireya Cisneros-Villanueva | Jose L. Moreno-Camacho | Jorge Rodriguez-Gallegos | Marco A. Luna-Ruiz Esparza | Miguel A. Fernández Rojas | Alfredo Mendoza-Vargas | Juan Pablo Reyes-Grajeda | Abraham Campos-Romero | Ofelia Angulo | Rosaura Ruiz | Claudia Sheinbaum-Pardo | José Sifuentes-Osornio | David Kershenobich | Alfredo Hidalgo-Miranda | Luis A. Herrera
The SARS-CoV-2 pandemic is one of the most concerning health problems around the globe. We reported the emergence of SARS-CoV-2 variant B.1.1.519 in Mexico City. We reported the effective reproduction number (Rt) of B.1.1.519 and presented evidence of its geographical origin based on phylogenetic analysis. We also studied its evolution via haplotype analysis and identified the most recurrent haplotypes. Finally, we studied the clinical impact of B.1.1.519. The B.1.1.519 variant was predominant between November 2020 and May 2021, reaching 90% of all cases sequenced in February 2021. It is characterized by three amino acid changes in the spike protein: T478K, P681H, and T732A. Its Rt varies between 0.5 and 2.9. Its geographical origin remain to be investigated. Patients infected with variant B.1.1.519 showed a highly significant adjusted odds ratio (aOR) increase of 1.85 over non-B.1.1.519 patients for developing a severe/critical outcome (p = 0.000296, 1.33–2.6 95% CI) and a 2.35-fold increase for hospitalization (p = 0.005, 1.32–4.34 95% CI). The continuous monitoring of this and other variants will be required to control the ongoing pandemic as it evolves.
显示更多 [+] 显示较少 [-]